PMC:7283670 / 108199-108412
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T18 | 27-31 | Body_part | denotes | body | http://purl.org/sig/ont/fma/fma256135 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T7025 | 79-87 | Chemical | denotes | solution | http://purl.obolibrary.org/obo/CHEBI_75958 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T923 | 0-137 | Sentence | denotes | Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no <60 min. |
| T924 | 138-213 | Sentence | denotes | Tocilizumab was administered according—continuous renal replacement therapy |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2092 | 138-149 | Chemical | denotes | Tocilizumab | MESH:C502936 |